Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy

References

• School of Health and Related Research (ScHARR) Technology Assessment Group. Technology assessment report commissioned by the NHS R&D HTA programme on behalf of the National Institute for Health and Clinical Excellence [online]. Available from www.nice.org.uk [Accessed 6 Oct 2006]
   Google Scholar
• NHS National Library for Health. Prodigy guidance: Hyperlipidaemia [online]. Available from http://www.prodigy.nhs.uk/hyperlipidaemia [Accessed 19 Oct 2006]
   Google Scholar
• National Cholesterol Education Program Expert Panel. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 1988;148:36–69
   PubMed Web of Science ®Google Scholar
• National Institutes of Health: National Heart, Lung, and Blood Institute. Second report of the Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Bethesda, MD: NIH Pub.No. 93–3095, 1993
   Google Scholar
• National Institutes of Health: National Heart, Lung, and Blood Institute. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [online]. Available from http://www.nhlbi.nih.gov/guidelines/cholesterol/upd-info_prof.htm [Accessed 6 Oct 2006]
   Google Scholar
• JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91 (Suppl 5):v1–52
   PubMedGoogle Scholar
• Smith SC, Jr., Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J Am Coll Cardiol 2006;47:2130–9
   PubMed Web of Science ®Google Scholar
• De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003;10:S1–10
   Google Scholar
• British National Formulary. Statins [online]. Available from http://www.bnf.org [Accessed 19 Oct 2006]
   Google Scholar
• Hippisley-Cox J, Cater R, Pringle M, Coupland C. Cross sectional survey of effectiveness of lipid lowering drugs in reducing serum cholesterol concentration in patients in 17 general practices. BMJ 2003;326: 689
   Google Scholar
• Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459–67
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. JAMA 2005;294:2437–45
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Wierzbicki AS, Daskalopoulou SS, et al. The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Curr Med Res Opin 2005;21:959–69
   PubMed Web of Science ®Google Scholar
• Daskalopoulou SS, Mikhailidis DP. Reaching goal in hyper-cholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Curr Med Res Opin 2006;22:511–28
   PubMed Web of Science ®Google Scholar
• Bestehorn K, Voller H, Benecke H, et al. Drug utilization of ezetimibe in rehabilitation centres: registry analysis of factors influencing prescription and effectiveness of treatment. Curr Med Res Opin 2006;22:631–9
   PubMed Web of Science ®Google Scholar
• Capps N. Total and low-density lipoprotein cholesterol responses to ezetimibe in clinical practice. Int J Clin Pract 2006;60:867–9
   PubMed Web of Science ®Google Scholar
• Rajapogalan S, Alemao E, Yin D. Ezetimibe prescribing patterns in UK clinical practice. European Atherosclerosis Society, Helsinki, Finland, June 2007
   Google Scholar
• EZETROL product insert. Merck Schering Plough Pharmaceuticals, North Wales, PA, 2005
   Google Scholar
• Kosoglou T, Meyer I, Musiol B. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor SCH 58235 and simvastatin. Atherosclerosis 2000;151: 135
   Google Scholar
• Kosoglou T, Meyer I, Veltri E. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Pharmacol 2002;54:309–19
   Google Scholar
• Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125–34
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Blazing MA, King TR, et al. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004;93:1487–94
   PubMed Web of Science ®Google Scholar
• Catapano AL, Davidson MH, Ballantyne CM, et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr Med Res Opin 2006;22:2041–53
   PubMed Web of Science ®Google Scholar
• Thomson Dialog. DataStar Web [online]. Available from www.datastarweb.com [Accessed 15 Dec 2005]
   Google Scholar
• The Cochrane Library. Cochrane Database of Systematic Reviews [online]. Available from www.mrw.interscience.wiley.com/cochrane/cochrane_clsysrev_subjects_fs.html
   Google Scholar
• National Institute for Health and Clinical Excellence. Specification for manufacturer/sponsor submission for Single Technology Appraisal (STA) [online]. Available from www.nice.org.uk/page.aspx?o=278614 [Accessed 6 Jan 2006]
   Google Scholar
• Cochran W. The combination of estimates from different experiments. Biometrics 1954;10:101–29
   Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–88
   PubMed Web of Science ®Google Scholar
• Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;6:556–85
   Google Scholar
• Brohet C, Banai S, Alings A-MW, et al. LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. Curr Med Res Opin 2005;21:571–8
   Google Scholar
• Farnier M, Volpe M, Massaad R, et al. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. Int J Cardiol 2005;102:327–32
   PubMed Web of Science ®Google Scholar
• Cruz-Fernández JM, Bedarida GV, Adgey J, et al. Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. Int J Clin Pract 2005;59:619–27
   Google Scholar
• Pearson TA, Denke MA, McBride PE, et al. A community- based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005;80:587–95
   PubMed Web of Science ®Google Scholar
• Gagné C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084–91
   Google Scholar
• Masana L, Mata P, Gagné C, et al. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo- controlled, 48-week extension study. Clin Ther 2005;27: 174–84
   Google Scholar
• Barrios V, Amabile N, Paganelli F, et al. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease. Int J Clin Pract 2005;59:1377–86
   PubMed Web of Science ®Google Scholar
• Pearson T, Denke M, McBride P, et al. An analysis of C-reactive protein and the efficacy of ezetimibe added to statin therapy. Atherosclerosis Suppl 2005;6:74, abs W12-P–051
   Google Scholar
• Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227–39
   PubMed Web of Science ®Google Scholar
• Bissonnette S, Habib R, Sampalis F, et al. Efficacy and tolerability of ezetimibe 10 mg/day coadministered with statins in patients with primary hypercholesterolemia who do not achieve target LDL-C while on statin monotherapy: a Canadian, multicentre, prospective study-the Ezetrol(R) Add-On Study. Can J Cardiol 2006;22:1035–44
   PubMed Web of Science ®Google Scholar
• Cheng JW. Rosuvastatin in the management of hyperlipidemia. Clin Ther 2004;26:1368–87
   PubMed Web of Science ®Google Scholar
• Catapano A, Brady WE, King TR, Palmisano J. Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials. Curr Med Res Opin 2005;21:1123–30
   PubMed Web of Science ®Google Scholar
• Ose L, Shah A, Davies MJ, et al. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis. Curr Med Res Opin 2006;22:823–35
   PubMed Web of Science ®Google Scholar
• Gazi IF, Mikhailidis DP. Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview. Expert Opin Ther Targets 2006;10:851–66
   PubMed Web of Science ®Google Scholar
• Sager PT, Capece R, Lipka L, et al. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis, 2005;179:361–7
   PubMed Web of Science ®Google Scholar
• Bays HE, Ose L, Fraser N, et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hyper-cholesterolemia. Clin Ther 2004;26:1758–73
   PubMed Web of Science ®Google Scholar
• Sager PT, Melani L, Lipka L, et al. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 2003;92:1414–18
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation, 2003;107: 2409–15
   PubMed Web of Science ®Google Scholar
• Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 2006;24:33–50
   PubMed Web of Science ®Google Scholar
• Davidson MH, Maccubbin D, Stepanavage M, et al. Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am J Cardiol 2006;97:223–8
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Guyton JR, Mazzone T, et al. Ezetimibe/ simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Mayo Clin Proc 2006;81:1579–88
   PubMed Web of Science ®Google Scholar
• Feldman T, Davidson M, Shah A, et al. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post hoc analysis of subpopulations from three pooled clinical trials. Clin Ther 2006;28:849–59
   PubMed Web of Science ®Google Scholar